Table 3.
Multivariate logistic models of Model 2 in Study 1
| Partial regression coefficient | Odds ratio (95% confidence interval) | P-value | |
|---|---|---|---|
| Step 1: Benign (1) vs. malignant lesions (0) | |||
| (Constant) | −3.3126 | ||
| Size | −0.1375 | 0.87 (0.82–0.93) | <0.001* |
| T2WI | |||
| Marked hyperintensity | 5.2645 | 193.34 (47.51–786.86) | <0.001* |
| Others | Reference category | ||
| T1WI | |||
| Without signal drop on OP | Reference category | ||
| With signal drop on OP | 1.5623 | 4.77 (0.82–27.79) | 0.082 |
| DWI | |||
| Isointensity | Reference category | ||
| Hyperintensity | 1.2802 | 3.60 (0.92–14.14) | 0.067 |
| Hypointensity | 4.8834 | 132.07 (12.01–1451.88) | <0.001* |
| APHE | |||
| Dot-like | 3.4136 | 30.37 (4.02–229.22) | 0.001* |
| Others | Reference category | ||
| HBP | |||
| No uptake of gadoxetate disodium | Reference category | ||
| Marked uptake of gadoxetate disodium | 3.8693 | 47.91 (8.17–280.97) | <0.001* |
| Moderate uptake of gadoxetate disodium | 1.7115 | 5.54 (0.80–38.09) | 0.082 |
| PVP or TP | |||
| Hypointensity | Reference category | ||
| Others | 0.8611 | 2.37 (0.72–7.82) | 0.158 |
| Step 2: HCC (1) vs. non-HCC malignant lesions (0) | |||
| (Constant) | −4.7852 | ||
| T2WI | |||
| Iso- or hypointensity | Reference category | ||
| Marked hyperintensity | 2.7356 | 15.42 (1.30–182.20) | 0.030* |
| Hyperintensity | 0.9572 | 2.60 (1.11–6.09) | 0.027* |
| T1WI | |||
| Without signal drop on OP | Reference category | ||
| With signal drop on OP | 1.3777 | 3.97 (1.03–15.33) | 0.046* |
| APHE | |||
| Dot-like or rim | Reference category | ||
| No | 2.1234 | 8.36 (2.89–24.22) | <0.001* |
| Part | 2.9058 | 18.28 (5.25–63.59) | <0.001* |
| Whole | 3.9804 | 53.54 (19.13–149.82) | <0.001* |
| HBP | |||
| Part uptake of gadoxetate disodium | Reference category | ||
| Whole uptake of gadoxetate disodium | 2.3740 | 10.74 (0.96–119.61) | 0.054 |
| No uptake of gadoxetate disodium | 0.6253 | 1.87 (0.63–5.58) | 0.262 |
| PVP or TP | |||
| Hypointensity | 1.9608 | 7.11 (2.84–17.78) | <0.001* |
| Others | Reference category | ||
*
P < 0.05. T2WI, T2-weighted image; T1WI, T1-weighted image; OP, opposed phase; DWI, diffusion-weighted image; APHE, arterial phase hyperenhancement; HBP, hepatobiliary phase; PVP, portal venous phase; TP, transitional phase; HCC, hepatocellular carcinoma.